1. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16–213 (NSC 141540) in L1210 Leukemia;Dombernowsky;Acta path. microbiol. scand.,1973
2. Activity of a new glycosidic lignan derivative (VP 16–213) related to podophyllotoxin in experimental tumors;Stähelin;Europ. J. Cancer,1973
3. Erste Resultate mit dem Epipodophyllotoxin-Derivat VP 16–213 bei der Behandlung akuter Leukämien;Cavalli;Schweiz. med. Wschr.,1975
4. Phase I clinical trial of weekly administration of 4′-demethylepipodophyllotoxin 9-(4,6-0-2-ethylidene-β-D-glucopyranoside) (VP 16–213, NSC 141540);Creaven;Cancer Chemother. Rep.,1974
5. Epipodophyllotoxin VP 16–213 in treatment of acute leukaemias, haematosarcomas and solid tumours;Brit. med. J.,1973